跳至主要内容
临床试验/NCT04714385
NCT04714385已完成不适用

Product Surveillance Registry (PSR) - Targeted Drug Delivery (TDD) - SynchroMed II European Post-Market Clinical Follow-up (PMCF)

Medtronic15 个研究点 分布在 8 个国家目标入组 209 人开始时间: 2017年2月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Medtronic
入组人数
209
试验地点
15
主要终点
Pump accuracy

研究概览

简要总结

The purpose of this study is to provide continuing evaluation and reporting of safety and performance of the SynchroMed II Infusion System within its intended use. Data will support post-market surveillance obligations.

详细描述

This study was originally posted under NCT01524276 and now posted alone to adapt to new ISO regulation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements
  • Patient has or is intended to receive or be treated with an eligible Medtronic product
  • Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment
  • The indication for implant meets approved indications
  • The patient can reasonably be expected to remain fully on label for a 48-month time period after implant

排除标准

  • Patient who is, or will be, inaccessible for follow-up
  • Patient with exclusion criteria required by local law
  • Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
  • There is no indication at enrollment (e.g., medical conditions, anticipated relocation, etc.) that the patient will be unable to complete 48 months of follow-up after implant

结局指标

主要结局

Pump accuracy

时间窗: 4 years

Demonstrate that the proportion of subjects treated as intended (p) with flow rate accuracy outside the interval of 0.75 to 1.25 (±25 percent) is \< 10 percent with 95 percent confidence at 4 years post implant.

次要结局

  • Pump survival(4 years)

研究者

发起方
Medtronic
申办方类型
Industry
责任方
Sponsor

研究点 (15)

Loading locations...

相似试验